INVESTOR RELATIONS

We believe our technology is a profound scientific breakthrough that could lead to a new paradigm for the identification, characterization and treatment of the multifactorial upstream etiology of CVD and other vascular pathophysiologies leading to predictive, curative and ultimately preventive outcomes. 

Technology Brief

  • Dr. Tunac developed and synthesized 9 active compounds leading to Arterez’ first abbreviated factorial 3-drug combo Embotricin™ as well as a 4-panel companion diagnostic tool to monitor endothelial glycocalyx health, GlycoCardia™, and finally the Glycocalyx Detritus Fingerprint™, a 7-panel universal diagnostic tool for chronic disease. These are Arterez’ first drug and diagnostics platform technologies in our development pipeline.

​

  • Embotricin™ proved to prevent plaque formation and /or restored the integrity of the endothelial glycocalyx as evidenced by the reduction in glycocalyx detritus shed in the bloodstream measured by individual biomarkers that make up the diagnostic panel, GlycoCardia™.

​

  • The effective dose in mice is 3mg/kg with no-observed-adverse-effect-level (NOAEL) up to 1,000 mg/kg in mice and 800mg/kg in rats confirmed by histopathology indicating Embotricin™ is non-toxic.

​

  • GlycoCardia™ utilizes 4 detritus biomarkers including heparan sulfate (HS), Hyaluronan synthase-1 (HAS-), syndecan-1 (SDC-1), and plasminogen activator inhibitor-1 (PAI-1). It is being developed as a companion diagnostic for plaque formation/regression to monitor Embotricin™ efficacy and will be presented as a surrogate end-point to the FDA.

​

  • The Glycalyx Detritus Fingerprint™ (GDF) consists of the 4 GlycoCardia™ components plus 3 additional biomarkers, including Gamma (γ′) fibrinogen (FGG), Growth differentiation factor 15 (GDF-15) and Pregnancy associated plasma protein (PAPP-A). The GDF 7-marker panel is being developed as a universal diagnostic tool for chronic diseases, equivalent to the DNA Fingerprint in forensics.

​

  • Licensing and/or co-development opportunities will be pursued for the diagnostic platform in 2022.

​

  • First in-human ‘proof of principle’ POC studies against hypertension, heart failure and coronary artery disease are expected to begin 2023 and will run concurrently.

​

  • Independent net present day intellectual property valuations include $105mm for our therapy vs 3 targeted indications and $471mm for our IP portfolio over-all.

 

Dr. Tunac and the Arterez’ team are honored to accept the invitation to present our technology innovations at the 2022 World Heart Conference in Singapore